Pernix Reinvention Comes Down To Execution
This article was originally published in The Pink Sheet Daily
Pernix has a new management team and a budding portfolio of CNS drugs, gained via M&A. Now the company needs to prove it can grow brands that compete in highly genericized markets and drive sustainable growth.
You may also be interested in...
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.